Review Article

Anti-Sclerostin Antibodies in the Treatment of Metabolic Bone Diseases

Ourania Trantafili¹, George I. Lambrou^1,2,3,4

1. Postgraduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Goudi, Athens, Greece
2. Laboratory for the Research of the Musculoskeletal System “Th. Garofalidis”, National and Kapodistrian University of Athens, Medical School, Kifissia, Athens, Greece
3. Choremeio Research Laboratory, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Goudi, Athens, Greece
4. University Research Institute of Maternal and Child Health & Precision Medicine, National and Kapodistrian University of Athens, Athens, Greece

---

Keywords: Antibodies, Bone, Osteoporosis, Romosozumab, Sclerostin

---

Abstract

The present review aimed to explore the treatment of metabolic bone diseases using anti-sclerostin antibodies, including Osteoporosis, Osteogenesis Imperfecta, Hypophosphatemia, Paget’s disease, Fibrous Dysplasia, Multiple Myeloma, Fluorosis, and McCune- Albright Syndrome. These disorders representing metabolic bone diseases are elaborated in the present work. Literature was searched from publicly available databases including PubMed, Scopus, and the Web of Science. Most studies, showed that bone mineral density rose and the risk of fracture was decreased in individuals after being treated with anti-sclerostin antibodies. However, the possibility that these antibodies may trigger cardiovascular events or venous thromboembolism was mentioned as a reason for alarm. Even though anti-sclerostin antibodies have shown promise in treating metabolic bone disorders, additional study is required to determine whether or not they pose any safety concerns.

---